U.S. Markets open in 2 hrs 41 mins
  • S&P Futures

    4,140.25
    -15.25 (-0.37%)
     
  • Dow Futures

    33,833.00
    -125.00 (-0.37%)
     
  • Nasdaq Futures

    13,853.50
    -43.75 (-0.31%)
     
  • Russell 2000 Futures

    2,216.40
    -12.90 (-0.58%)
     
  • Crude Oil

    64.00
    +0.62 (+0.98%)
     
  • Gold

    1,770.70
    +0.10 (+0.01%)
     
  • Silver

    25.92
    +0.08 (+0.30%)
     
  • EUR/USD

    1.2057
    +0.0016 (+0.1326%)
     
  • 10-Yr Bond

    1.6010
    0.0000 (0.00%)
     
  • Vix

    18.37
    +2.12 (+13.05%)
     
  • GBP/USD

    1.3977
    -0.0007 (-0.0531%)
     
  • USD/JPY

    108.3810
    +0.2310 (+0.2136%)
     
  • BTC-USD

    56,059.39
    -828.70 (-1.46%)
     
  • CMC Crypto 200

    1,265.56
    -33.39 (-2.57%)
     
  • FTSE 100

    6,934.58
    -65.50 (-0.94%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 25%?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.

In this article we are going to estimate the intrinsic value of Champions Oncology, Inc. (NASDAQ:CSBR) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Champions Oncology

The calculation

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

-US$808.0k

US$1.72m

US$1.93m

US$3.77m

US$6.40m

US$8.49m

US$10.5m

US$12.3m

US$13.8m

US$15.1m

Growth Rate Estimate Source

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Est @ 32.77%

Est @ 23.55%

Est @ 17.1%

Est @ 12.58%

Est @ 9.42%

Present Value ($, Millions) Discounted @ 7.1%

-US$0.8

US$1.5

US$1.6

US$2.9

US$4.5

US$5.6

US$6.5

US$7.1

US$7.4

US$7.6

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$43m

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.1%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$15m× (1 + 2.0%) ÷ (7.1%– 2.0%) = US$304m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$304m÷ ( 1 + 7.1%)10= US$153m

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$196m. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$11.6, the company appears a touch undervalued at a 25% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
dcf

The assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Champions Oncology as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.1%, which is based on a levered beta of 0.972. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Champions Oncology, there are three additional factors you should explore:

  1. Risks: Every company has them, and we've spotted 2 warning signs for Champions Oncology you should know about.

  2. Future Earnings: How does CSBR's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.